OncoCyte Co. (NASDAQ:OCX) Shares Acquired by FNY Investment Advisers LLC

FNY Investment Advisers LLC lifted its stake in shares of OncoCyte Co. (NASDAQ:OCX) by 15.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 49,377 shares of the company’s stock after purchasing an additional 6,481 shares during the period. FNY Investment Advisers LLC owned approximately 0.29% of OncoCyte worth $117,000 at the end of the most recent quarter.

Separately, Geode Capital Management LLC raised its holdings in OncoCyte by 12.2% during the 3rd quarter. Geode Capital Management LLC now owns 103,980 shares of the company’s stock worth $296,000 after buying an additional 11,289 shares during the period. Institutional investors and hedge funds own 55.35% of the company’s stock.

OncoCyte Price Performance

Shares of OncoCyte stock opened at $2.15 on Wednesday. OncoCyte Co. has a 1 year low of $1.97 and a 1 year high of $3.57. The stock has a 50-day moving average price of $2.45 and a 200 day moving average price of $2.86.

OncoCyte (NASDAQ:OCX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.54). OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. The company had revenue of $0.12 million during the quarter. During the same period last year, the business earned ($0.57) earnings per share. On average, equities analysts forecast that OncoCyte Co. will post -2.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other OncoCyte news, Director Andrew Arno acquired 12,500 shares of the business’s stock in a transaction that occurred on Thursday, December 26th. The shares were purchased at an average price of $2.11 per share, with a total value of $26,375.00. Following the completion of the transaction, the director now owns 81,554 shares in the company, valued at $172,078.94. The trade was a 18.10 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Patrick W. Smith bought 90,219 shares of the firm’s stock in a transaction on Thursday, December 26th. The stock was acquired at an average cost of $2.13 per share, with a total value of $192,166.47. Following the completion of the transaction, the insider now directly owns 1,773,903 shares of the company’s stock, valued at approximately $3,778,413.39. This represents a 5.36 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 122,719 shares of company stock worth $264,341 in the last quarter. 1.58% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

OCX has been the subject of several recent analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $4.25 target price on shares of OncoCyte in a report on Wednesday, November 13th. StockNews.com started coverage on shares of OncoCyte in a research note on Monday. They issued a “sell” rating for the company.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.